Renalytix AI and AstraZeneca partner for precision medicine strategies

24 August 2020 (Last Updated August 24th, 2020 11:35)

Artificial intelligence (AI)-enabled in vitro diagnostics company Renalytix AI has partnered with AstraZeneca to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases.

Renalytix AI and AstraZeneca partner for precision medicine strategies
Chronic kidney disease is a serious, progressive condition defined by decreased kidney function. Credit: Kristoffer Lindskov Hansen, Michael Bachmann Nielsen and Caroline Ewertsen.

Artificial intelligence (AI)-enabled in vitro diagnostics company Renalytix AI has partnered with AstraZeneca to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases.

In the first stage of the collaboration, Renalytix AI’s AI-based in vitro diagnostic platform KidneyIntelX will be used to evaluate improving outcomes for patients with chronic kidney disease (CKD) and its complications.

Based on the study outcomes, the companies also plan to initiate a multi-centre, randomised controlled trial.

The study will evaluate uptake and adherence to new potassium-binding agents in CKD and hyperkalemia patients.

It will improve guideline-based standard-of-care for optimal utilisation of existing and novel therapeutics, using the KidneyIntelX testing platform and proprietary care management software.

The studies will be conducted in coordination with the Mount Sinai Health System, where KidneyIntelX testing and care management software are presently being deployed for commercial clinical use.

RenalytixAI board member Barbara Murphy said: “We believe this collaboration will define how we can leverage KidneyIntelX to improve the care and outcomes for patients affected by chronic diseases such as kidney disease, diabetes and cardiovascular disease.

“By using a more personalised approach, our initial goal is to help realise improved outcomes for more than 240,000 patients with chronic kidney disease within the Mount Sinai Health System.”

AstraZeneca US Renal-Cardio vice-president Tarek Rabah said: “This collaborative approach reflects the shared vision of AstraZeneca and RenalytixAI to develop meaningful solutions to tackle significant challenges in healthcare in a holistic way.

“We are committed to revolutionising kidney care by continuing to drive innovation. An important component of our work is identifying patients with significant unmet need and providing them with more personalised interventions.”

CKD affects nearly 37 million adults in the US. More than 850 million people are estimated to be affected by CKD and acute kidney injury (AKI), and are on renal replacement therapy (RRT) globally.